The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the invasive procedure.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.

CytoMed Therapeutics has signed a business and research collaboration agreement with SunAct Cancer Institute for a clinical trial in India.

After disappointing Phase IIb results for avicursen in December, Percheron will adopt a three-pronged business strategy.

Chime Biologics and Mabgeek have completed the Process Performance Qualification (PPQ) for the humanised anti-IL-4Rα monoclonal antibody, MG-K10, advancing it into Phase III clinical trials for a ...

Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...

The Australian Government has announced the ‘2024 Clinical Trial Enabling Infrastructure’ grant opportunity, offering A$35.7m for research.

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).